Charles Schwab
WHWK

Charles Schwab’s Whitehawk Therapeutics WHWK Stock Holding History

Charles Schwab’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$361K Buy
+78,832
New +$328K ﹤0.01% 3298
2024
Q2 		– Sell
-37,075
Closed -$86.8K – 3692
2024
Q1 		$86.8K Sell
37,075
-8,294
-18% -$16K ﹤0.01% 3318
2023
Q4 		$91.6K Hold
45,369
– – ﹤0.01% 3354
2023
Q3 		$220K Hold
45,369
– – ﹤0.01% 3270
2023
Q2 		$310K Buy
45,369
+4,150
+10% +$32.3K ﹤0.01% 3218
2023
Q1 		$298K Hold
41,219
– – ﹤0.01% 3089
2022
Q4 		$529K Buy
41,219
+4,966
+14% +$64.8K ﹤0.01% 2993
2022
Q3 		$513K Sell
36,253
-3,597
-9% -$47.3K ﹤0.01% 2996
2022
Q2 		$491K Buy
+39,850
New +$592K ﹤0.01% 3090
2021
Q2 		– Sell
-856
Closed -$17K – 3552
2021
Q1 		$17K Hold
856
– – ﹤0.01% 3485
2020
Q4 		$13K Hold
856
– – ﹤0.01% 3390
2020
Q3 		$20K Hold
856
– – ﹤0.01% 3312
2020
Q2 		$17K Hold
856
– – ﹤0.01% 3301
2020
Q1 		$8K Hold
856
– – ﹤0.01% 3221
2019
Q4 		$9K Hold
856
– – ﹤0.01% 3175
2019
Q3 		$9K Hold
856
– – ﹤0.01% 3176
2019
Q2 		$12K Hold
856
– – ﹤0.01% 3209
2019
Q1 		$12K Buy
+856
New +$36.8K ﹤0.01% 3192

Other funds holding WHWK

YF
Yu Fan $108M AUM 137.54% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $136M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Charles Schwab's WHWK Position: Q2 2026 in Review

Charles Schwab opened a new position in Whitehawk Therapeutics (WHWK) in Q2 2026: 78,832 shares worth $361K. The stake represents ﹤0.01% of the portfolio and ranks #3298 among its holdings. This is a return to the name: Charles Schwab previously reported a position in WHWK as recently as Q1 2024.

Charles Schwab first reported a position in WHWK in Q1 2019 and has held it in 18 quarters since. The position peaked at $529K in Q4 2022. 78 funds tracked by Wall St. Rank hold WHWK as of Q2 2026.

  • Charles Schwab held 78,832 shares of Whitehawk Therapeutics worth $361K as of Q2 2026.
  • Whitehawk Therapeutics was a new Charles Schwab position in Q2 2026.
  • Whitehawk Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3298 holding.
  • Charles Schwab first reported a position in Whitehawk Therapeutics in Q1 2019 and has held it in 18 quarters since.
  • Charles Schwab's Whitehawk Therapeutics position peaked at $529K in Q4 2022.
  • 78 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.